✦ March 8: The FDA gave accelerated approval to Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) for the first-line treatment of locally advanced or metastatic triple-negative breast cancer in people whose tumors express programmed death-ligand 1 (PD-L1). The agency initially approved Tecentriq from Genentech USA, Inc., a Roche unit, in May 2016 (RSP 6/16, p. 6), and it first approved Abraxane, from Celgene Corp., in 2005. Tecentriq also has approvals in urothelial carcinoma and non-small cell lung cancer (NSCLC). Dosing for the newest use is 840 mg of Tecentriq infused intravenously over 60 minutes, followed by 100 mg/m2 of Abraxane. For each 28-day cycle, Tecentriq is administered on days one and 15, while Abraxane is administered on days one, eight and 15. Visit www.tecentriq.com.